Clinical Research Directory
Browse clinical research sites, groups, and studies.
Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia
Sponsor: Daewoong Pharmaceutical Co. LTD.
Summary
This study is a large-scale, prospective, multi-center, and non-interventional observation study to observe blood pressure and blood lipid changes and safety during administration of olomax tablets for 24 weeks in hypertensive patients with dyslipidemia.
Official title: Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia: a Multi-center-database Real-world Study
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
OBSERVATIONAL
Enrollment
4000
Start Date
2022-06-20
Completion Date
2025-12-31
Last Updated
2025-08-24
Healthy Volunteers
No
Conditions
Interventions
Olmesartan Medoxomil/ Amlodipine Besylate/ Rosuvastatin Ca
Olomax Tab 20/5/5mg Olomax Tab 20/5/10mg Olomax Tab 40/5/5mg Olomax Tab 40/5/10mg
Locations (1)
The Catholic University of Korea, Seoul ST. Mary's Hospital
Seoul, South Korea